Thyroid disorders are commonly associated with coagulopathy. Patients with hyperthyroidism have increased risk for developing thromboembolic accidents, which are favoured by a simultaneous presence of antiphospholipid antibodies syndrome. in this paper, we describe the case of a patient with Graves' disease, who developed strokes with antiphospholipid antibodies syndrome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939437 | PMC |
| http://dx.doi.org/10.1155/2010/624152 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive factors influencing hypothyroidism following the radioactive iodine treatment of Graves' disease in different periods.
Sci Rep
December 2024
Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
In China, due to the risks of hypothyroidism after radioiodine treatment, radioiodine is not commonly used as a first-line treatment. In this study, factors influencing the development of hypothyroidism after I therapy for Graves' hyperthyroidism were evaluated. This was a retrospective study with a 12-month follow-up.
View Article and Find Full Text PDF[Glucocorticoid-resistant forms of endocrine ophthalmopathy].
Vestn Oftalmol
December 2024
Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
Endocrine ophthalmopathy (EO; also called Graves' ophthalmopathy, thyroid eye disease) is a common extrathyroidal manifestation of Graves' disease, characterized by the presence of autoimmune inflammatory process in the orbital soft tissues. The prevalence of EO is approximately 10 cases per 10.000 population, higher in individuals over 50 years old.
View Article and Find Full Text PDFA Belgian single centre outcome study of radioiodine treatment in adolescents with Graves' disease.
Sci Rep
December 2024
Division of Paediatric Endocrinology, Vrije Universiteit Brussel, UZ Brussel, Laarbeeklaan 110, Brussels, 1090, Belgium.
Up to 80% of children/adolescents with Graves' disease (GD) may require second-line treatment with either surgery or radioactive iodine (RAI) therapy after treatment with antithyroid drugs. These interventions aim to induce permanent hypothyroidism, but are not always successful. We aimed to evaluate the initial success rate (within the first year) of RAI treatment and its determining factors as second-line treatment in teenagers with GD.
View Article and Find Full Text PDFEpidemiology of Lymphatic Filariasis Antigen and Microfilaria in Samoa, 2019: 7-9 Months Post Triple-Drug Mass Administration.
Trop Med Infect Dis
December 2024
Centre for Clinical Research, The University of Queensland, Brisbane, QLD 4006, Australia.
The elimination of lymphatic filariasis (LF) as a public health problem remains an ongoing challenge in the Pacific region. This study reports on antigen (Ag) and microfilaria (Mf) prevalence in Samoa in 2019, 7-9 months after the completion of the first round of triple-drug mass drug administration (MDA). It evaluates the effectiveness of the intervention for reducing Ag prevalence to below a 2% threshold, and how this differs between 5-9-year-olds and ≥10-year-olds.
View Article and Find Full Text PDFManagement of Graves' upper eyelid retraction (GUER): A review.
Indian J Ophthalmol
December 2024
Hariram Motumal Nasta and Renu Hariram Nasta Ophthalmic Plastic Surgery Service, L.V. Prasad Eye Institute, Hyderabad, Telangana, India.
Graves' disease, a common autoimmune disorder, characteristically presents with upper eyelid retraction, causing significant functional and cosmetic concerns for affected individuals. The management of Graves' upper eyelid retraction has evolved significantly over recent years, with various surgical and non-surgical interventions. An ideal procedure is predictable and easily repeatable.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!